Sells prescription medicines for patients with blood disorders and cancers, including TAVALISSE, REZLIDHIA and GAVRETO.
10-K for FY2025, filed Mar 3, 2026We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with…View ↗
TAVALISSE® (fostamatinib disodium hexahydrate) is our first FDA-approved product and is the only approved oral spleen tyrosine kinase (SYK)…View ↗
REZLIDHIA® (olutasidenib) is our second FDA-approved product and indicated for the treatment of adult patients with relapsed or refractory…View ↗
GAVRETO® (pralsetinib) is our third FDA-approved product which we began commercializing in June 2024. GAVRETO is a once daily, small…View ↗
Customers pay for medicines when specialty distributors receive delivery. Collaboration partners pay for license rights, milestones, drug supplies and royalties on licensed-product sales.
10-K for FY2025, filed Mar 3, 2026Revenues from product sales are recognized when our customers obtain control of our product, which occurs at a point in time upon delivery.…View ↗
In the normal course of business, we conduct research and development programs independently and in connection with our corporate…View ↗
Upfront License Fees: If the license to our intellectual property is determined to be distinct from the other performance obligations…View ↗
10-K for FY2025, filed Mar 3, 2026
FY2025 revenue by product or service ↗$294.3M
10-K for FY2025, filed Mar 3, 2026
$294.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Total product sales, net
Sold outright
10-K for FY2025, filed Mar 3, 2026 |
79%
FY2022: 64%
|
Total product sales, net, FY2025
$232M Sources
|
Sold outright |
|
Total revenues from collaborations
|
21%
FY2022: 32%
|
Total revenues from collaborations, FY2025
$62M Sources
|
|
|
Government contracts
|
0.1%
FY2022: 3.7%
|
Government contracts, FY2025
$265K Sources
|
U.S. product sales go to specialty distributors, which resell to specialty pharmacies, health care providers, hospitals and clinics. Collaboration partners license rights, buy drug supplies and pay royalties or milestones.
10-K for FY2025, filed Mar 3, 2026Revenues from product sales are recognized when our customers obtain control of our product, which occurs at a point in time upon delivery.…View ↗
In the normal course of business, we conduct research and development programs independently and in connection with our corporate…View ↗
In 2025, contract revenues from collaborations consisted primarily of non-cash revenue of $40.0 million related to the release of cost…View ↗
10-K for FY2025, filed Mar 3, 2026
Year Ended December 31, 2025 2024 2023 McKesson Corporation 42 % 45 % 43 % Cencora Inc. 19 % 20 % 21 % Cardinal Health, Inc. * 13 % 25 %…View ↗
Yes. Its net income in FY2025 was larger than its revenue.
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 4, 2026
Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations…View ↗
8-K, filed Apr 21, 2026
Pursuant to the terms of the Agreement, Lilly has elected to terminate the Agreement in its entirety. The termination will become effective…View ↗
Growing. Revenue grew 97% in 4 years, from $149.2M in FY2021 to $294.3M in FY2025, about 19% a year.
Added GAVRETO to marketed medicines
The latest report describes GAVRETO as a marketed medicine for lung and thyroid cancers; the older report describes TAVALISSE and REZLIDHIA as its commercial products.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 3, 2026GAVRETO® (pralsetinib) is our third FDA-approved product which we began commercializing in June 2024. GAVRETO is a once daily, small…View ↗
Competes with Sanofi, Novartis International, Amgen, Dova Pharmaceuticals, and Teva Pharmaceutical Industries
10-K for FY2025, filed Mar 3, 2026The FDA recently approved the product WAYRILZTM (Sanofi SA) for the treatment of adults with persistent or chronic ITP. Other products in…View ↗
Loading...